{"id":2878,"date":"2018-08-10T17:30:10","date_gmt":"2018-08-10T12:00:10","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2878"},"modified":"2021-07-24T12:57:01","modified_gmt":"2021-07-24T07:27:01","slug":"the-business-cocktail-36","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-36","title":{"rendered":"Sarepta\u2019s deal; Fund raisings for Apexigen; Novo funded rare disease startup"},"content":{"rendered":"

Sarepta builds in gene therapy with $30M Lacerta deal<\/strong><\/p>\n

Sarepta has dampen its enthusiasm for an ongoing gene therapy candidate. Sarepta has made a tie-up with lacerta that will add 3 more programs to 8 already existing and are ready to expand its focus beyond muscular dystrophy. Sarepta\u00a0has committed to pay Lacerta development and sales-based milestones adding single-digit royalties on net sales under the terms of the deal. The tie-up with Lacerta follows an alliance with Myonexus for five gene therapy programs focusing on limb girdle muscular dystrophy (LGMD).Sarepta\u2019s lead DMD gene therapy was placed under hold because of a\u00a0quality <\/strong>issue<\/strong>\u00a0.shares in the company\u00a0raised<\/strong>\u00a0on the strength of data from 3 patients in a phase 1\/2 study that showed an increase in microdystrophin to a level that might stop, or even reverse, DMD progression.<\/p>\n

Fund raisings give Apexigen $73M for immune-oncology<\/a><\/strong><\/p>\n

Apexigen has raised $73 million for clinical testing of CD40-targeting immune-oncology candidate. The second and third fundraising has happened 5 years after the initial round that raised $20 million.\u00a0\u00a0 Apexigen is already advancing lead CD40 against APX005M on a broad front, with eight clinical trials in play both as a monotherapy and in combination with other drugs.<\/p>\n

Novo funded rare disease startup Therachon with $60M\u00a0<\/strong><\/p>\n

Therachon has\u00a0raised<\/span><\/b><\/a>\u00a0$60 million , <\/span>funded by Novo Holdings & joined by new investors Cowen Healthcare Investments, Pfizer Ventures and funds managed by Tekla Capital Management.\u00a0<\/span>Therachon\u2019s plan is to prevent the excessive signaling through the administration of a soluble human form of FGFR3. The protein will serve as a decoy receptor that stops FGF from binding to the mutant form of FGFR3.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

Sarepta builds in gene therapy with $30M Lacerta deal Sarepta has dampen its enthusiasm for an ongoing gene therapy candidate. Sarepta has made a tie-up with lacerta that will add 3 more programs to 8 already existing and are ready to expand its focus beyond muscular dystrophy. Sarepta\u00a0has committed to pay Lacerta development and sales-based […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[1410,258,877,626,3864],"industry":[17225],"therapeutic_areas":[17235,17228,17234],"class_list":["post-2878","post","type-post","status-publish","format-standard","hentry","category-notizia","tag-apexigen","tag-gene-therapy","tag-novo-nordisk","tag-sarepta","tag-therachon","industry-pharmaceutical","therapeutic_areas-cell-and-gene-therapy","therapeutic_areas-oncology","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"\nSarepta\u2019s deal; Fund raisings for Apexigen; Novo funded startup<\/title>\n<meta name=\"description\" content=\"Sarepta builds in gene therapy with $30M Lacerta dealSarepta has dampen its enthusiasm for an ongoing gene...............\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-36\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sarepta\u2019s deal; Fund raisings for Apexigen; Novo funded startup\" \/>\n<meta property=\"og:description\" content=\"Sarepta builds in gene therapy with $30M Lacerta dealSarepta has dampen its enthusiasm for an ongoing gene...............\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-36\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-08-10T12:00:10+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:01+00:00\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sarepta\u2019s deal; Fund raisings for Apexigen; Novo funded startup","description":"Sarepta builds in gene therapy with $30M Lacerta dealSarepta has dampen its enthusiasm for an ongoing gene...............","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-36","og_locale":"en_US","og_type":"article","og_title":"Sarepta\u2019s deal; Fund raisings for Apexigen; Novo funded startup","og_description":"Sarepta builds in gene therapy with $30M Lacerta dealSarepta has dampen its enthusiasm for an ongoing gene...............","og_url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-36","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-08-10T12:00:10+00:00","article_modified_time":"2021-07-24T07:27:01+00:00","author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-36","url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-36","name":"Sarepta\u2019s deal; Fund raisings for Apexigen; Novo funded startup","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"datePublished":"2018-08-10T12:00:10+00:00","dateModified":"2021-07-24T07:27:01+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Sarepta builds in gene therapy with $30M Lacerta dealSarepta has dampen its enthusiasm for an ongoing gene...............","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-36"]}]},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":null,"coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Apexigen<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Gene therapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Novo Nordisk<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Sarepta<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Therachon<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Apexigen<\/span>","<span class=\"advgb-post-tax-term\">Gene therapy<\/span>","<span class=\"advgb-post-tax-term\">Novo Nordisk<\/span>","<span class=\"advgb-post-tax-term\">Sarepta<\/span>","<span class=\"advgb-post-tax-term\">Therachon<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Aug 10, 2018","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Aug 10, 2018 5:30 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2878","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2878"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2878\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2878"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2878"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2878"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2878"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2878"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}